Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed non-small cell lung cancer meeting ≥ 1 of
the following criteria:

- Stage IIIB disease

- Stage II or IIIA disease, meeting the following criteria:

- Considered nonresectable

- Pleural effusion present

- Measurable disease

- Must have received a prior regimen of radiotherapy and chemotherapy comprising
docetaxel and carboplatin

- Tumor volume must be able to be encompassed in the radiation field

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy > 12 weeks

- Cardiac function compatible with radiotherapy

- Neutrophil count ≥ 2,000/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 10 g/dL

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.25 times ULN

- AST and ALT ≤ 1.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- Not pregnant or nursing

- No other malignancy in the past 10 years except basal cell skin cancer or carcinoma
in situ of the cervix

- No active infection

- No inflammatory bowel disease

- No severe congestive heart failure

- No severe hepatic disease defined as albumin < 25 g/L or Child-Pugh score ≥ 10

- No severe renal disease defined as creatinine clearance < 30 mL/min

- No known hypersensitivity to sulfonamides, the study or it's excipients, or
polysorbate 80

- No known hypersensitivity of NSAIDs, salicylic acid, or cyclo-oxygenase-2 inhibitors

- No familial, social, geographical, or psychological condition that would preclude
study compliance

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 30 days since participation in another clinical study

- More than 1 month since prior therapy for gastrointestinal ulcers

- No concurrent fluconazole, ketoconazole, lithium, or dextromethorphan

- No other concurrent anticancer treatment including chemotherapy, hormonal therapy,
radiotherapy, immunotherapy, or biologic response modifier therapy

- No concurrent aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)

- Low-dose aspirin or NSAIDs for a duration of ≤ 1 week during the past 3 months
allowed